Atrial Fibrillation in Patients With Cardiomyopathy: Prevalence and Clinical Outcomes From Real-World Data

被引:23
|
作者
Buckley, Benjamin J. R. [1 ,2 ,3 ]
Harrison, Stephanie L. [1 ,2 ,3 ]
Gupta, Dhiraj [2 ]
Fazio-Eynullayeva, Elnara [4 ]
Underhill, Paula [4 ]
Lip, Gregory Y. H. [1 ,2 ,3 ,5 ]
机构
[1] Univ Liverpool, Liverpool Ctr Cardiovasc Sci, William Henry Duncan Bldg, Liverpool L7 8TX, Merseyside, England
[2] Liverpool Heart & Chest Hosp, Liverpool, Merseyside, England
[3] Univ Liverpool, Dept Cardiovasc & Metab Med, Inst Life Course & Med Sci, Liverpool, Merseyside, England
[4] TriNetX LLC, London, England
[5] Aalborg Univ, Dept Clin Med, Aalborg, Denmark
来源
关键词
atrial fibrillation; cardiomyopathy; comorbidity; MACE; preventive cardiology; secondary prevention; CATHETER ABLATION; HYPERTROPHIC CARDIOMYOPATHY; SYSTOLIC DYSFUNCTION; HEART-FAILURE; MORBIDITY; RISK;
D O I
10.1161/JAHA.121.021970
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Cardiomyopathy is a common cause of atrial fibrillation (AF) and may also present as a complication of AF. However, there is a scarcity of evidence of clinical outcomes for people with cardiomyopathy and concomittant AF. The aim of the present study was therefore to characterize the prevalence of AF in major subtypes of cardiomyopathy and investigate the impact on important clinical outcomes. Methods and Results A retrospective cohort study was conducted using electronic medical records from a global federated health research network, with data primarily from the United States. The TriNetX network was searched on January 17, 2021, including records from 2002 to 2020, which included at least 1 year of follow-up data. Patients were included based on a diagnosis of hypertrophic, dilated, or restrictive cardiomyopathy and concomitant AF. Patients with cardiomyopathy and AF were propensity-score matched for age, sex, race, and comorbidities with patients who had a cardiomyopathy only. The outcomes were 1-year mortality, hospitalization, incident heart failure, and incident stroke. Of 634 885 patients with cardiomyopathy, there were 14 675 (2.3%) patients with hypertrophic, 90 117 (7.0%) with restrictive, and 37 685 (5.9%) with dilated cardiomyopathy with concomitant AF. AF was associated with significantly higher odds of all-cause mortality (odds ratio [95% CI]) for patients with hypertrophic (1.26 [1.13-1.40]) and dilated (1.36 [1.27-1.46]), but not restrictive (0.98 [0.94-1.02]), cardiomyopathy. Odds of hospitalization, incident heart failure, and incident stroke were significantly higher in all cardiomyopathy subtypes with concomitant AF. Among patients with AF, catheter ablation was associated with significantly lower odds of all-cause mortality at 12 months across all cardiomyopathy subtypes. Conclusions Findings of the present study suggest AF may be highly prevalent in patients with cardiomyopathy and associated with worsened prognosis. Subsequent research is needed to determine the usefulness of screening and multisdisciplinary treatment of AF in this population.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Real-world evaluation Of anticoagulant Treatment patterns in patients with Atrial fibrillation: Data from multicenter ROTA study
    Kocabas, Umut
    Ergin, Isil
    Yavuz, Veysel
    Murat, Selda
    Ozdemir, Ibrahim
    Genc, Omer
    Altin, Cihan
    Tuner, Hasim
    Meric, Bengisu Keskin
    Coner, Ali
    Yuce, Elif Ilkay
    Boyraz, Bedrettin
    Aslan, Onur
    Dal, Ahmet
    Sen, Taner
    Ibisoglu, Ersin
    Erdogan, Aslan
    Ozgeyik, Mehmet
    Demir, Mevlut
    Bilgel, Ziya Gokalp
    Sengor, Busra Guvendi
    Urgun, Orsan Deniz
    Dogdus, Mustafa
    Tekin, Deniz Dilan Naki
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2022, 26 : S61 - S62
  • [32] Catheter ablation for atrial fibrillation in patients with clinical heart failure: real-world experience from a tertiary centre
    Ines Aguiar Neves, A. I. Ana
    Teixeira, R.
    Leite, M.
    Nunes, F.
    Silva, M. Ribeiro
    Silva, G. Santos
    Almeida, M.
    Lobo, A.
    Almeida, J.
    Fonseca, P.
    Oliveira, M.
    Goncalves, H.
    Primo, J.
    Fontes-Carvalho, R.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 10 - 10
  • [33] Real-world clinical data of atrial fibrillation patients treated with direct oral anticoagulants in combination with or without antiplatelet therapy
    Sotomi, Y.
    Hirata, A.
    Amiya, R.
    Nakano, T.
    Takeda, Y.
    Makino, N.
    Nakatani, S.
    Higuchi, Y.
    EUROPEAN HEART JOURNAL, 2018, 39 : 1264 - 1264
  • [34] The impact of body mass index for atrial fibrillation ablation; real-world data on outcomes and quality of life
    Vermeer, J.
    Houterman, S.
    Medendorp, N. M.
    Van Der Voort, P. H.
    Dekker, L. R. C.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [35] The Effect of Different Oral Anticoagulants on Vascular Outcomes in Stroke With Atrial Fibrillation: A Real-world Data.
    Seo, Woo-Keun
    Kim, Joon-Tae
    Chung, Jong-Won
    Song, Tae-Jin
    Kim, Yong-Jae
    Kim, Bum Joon
    Heo, Sung Hyuk
    Jung, Jin-Man
    Oh, Kyungmi
    Kim, Chi Kyung
    Yu, Sungwook
    Park, Kwang Yeol
    Kim, Jeong-Min
    Park, Jong-Ho
    Choi, Jay Chol
    Park, Man-Seok
    Choi, Kang-Ho
    Hwang, Yang-Ha
    Bang, Oh Young
    Kim, Geong-Moon
    STROKE, 2019, 50
  • [36] Atrial fibrillation and stroke outcomes in Scotland: real-world evidence from a contemporary, national dataset
    Ciminata, G.
    Venson, R.
    Geue, C.
    Quinn, T.
    Trotter, R.
    Pollock, K.
    Lister, S.
    EUROPEAN HEART JOURNAL, 2020, 41 : 2432 - 2432
  • [37] The impact of body mass index for atrial fibrillation ablation; real-world data on outcomes and quality of life
    Vermeer, J.
    Houterman, S.
    Medendorp, N. M.
    van der Voort, P. H.
    Dekker, L. R. C.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [38] Evaluation of the Impact of Catheter Ablation Procedure on Outcomes and Economic Burden in Patients with Atrial Fibrillation: Real-World Data from Italian Administrative Databases
    Esposti, Luca Degli
    Dovizio, Melania
    Leogrande, Melania
    Perrone, Valentina
    De Ponti, Roberto
    HEALTHCARE, 2022, 10 (12)
  • [39] Nephroprotective and anticoagulant therapy in patients with atrial fibrillation and chronic kidney disease: real-world data
    Listratov, A. I.
    Ivanov, I. I.
    Ziskina, N. K.
    Efimenko, V. V.
    Zhavoronkova, A. V.
    Miliakova, E. S.
    Kudrjavtseva, A. A.
    Napalkov, D. A.
    Sokolova, A. A.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2024, 20 (04)
  • [40] Incidence and impact of atrial fibrillation in heart failure patients: real-world data in a large community
    Diaz, Javier
    Martinez, Fernando
    Miguel Calderon, Jose
    Fernandez, Antonio
    Sauri, Inmaculada
    Uso, Ruth
    Luis Trillo, Jose
    Redon, Josep
    Jose Forner, Maria
    ESC HEART FAILURE, 2022, 9 (06): : 4230 - 4239